What Is the Difference Between Zepbound and Wegovy? Active Ingredient, Mechanism, Efficacy, and Cost Compared

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound contains tirzepatide (dual GLP-1/GIP agonist), while Wegovy contains semaglutide (GLP-1 agonist only). The additional GIP receptor activation in Zepbound produces 3 to 5 percentage points greater total body weight loss in head-to-head comparisons.
• In the SURMOUNT-1 trial, tirzepatide 15 mg produced 20.9% mean weight loss vs 14.9% for semaglutide 2.4 mg in published indirect comparisons. Direct head-to-head trial data (SURPASS-2) shows tirzepatide superiority for glycemic control and weight loss in diabetes populations.
• Zepbound causes more nausea during titration (29% vs 20% for Wegovy) but comparable rates after dose stabilization. Both carry similar cardiovascular benefit signals, though Wegovy has more published outcomes data.
• Brand-name Wegovy costs $1,349 per month vs $1,059 for Zepbound (2026 list prices). Compounded versions of both active ingredients cost $299 to $399 per month through platforms like FormBlends, with identical mechanisms to brand-name products.

Direct answer (40-60 words)

Zepbound (tirzepatide) activates both GLP-1 and GIP receptors, while Wegovy (semaglutide) activates GLP-1 receptors only. The dual-receptor mechanism produces approximately 6 percentage points more total body weight loss (20.9% vs 14.9% at maximum doses). Both slow gastric emptying and suppress appetite, but tirzepatide shows stronger efficacy in published trials with modestly higher nausea rates during titration.

Table of contents

1. The core mechanism difference: one receptor vs two
2. Head-to-head efficacy data: what the trials actually show
3. Side effect profiles compared: nausea, reflux, and discontinuation rates
4. Dosing schedules and titration protocols
5. Cost comparison: brand-name vs compounded versions
6. Cardiovascular outcomes: published data vs ongoing trials
7. What most articles get wrong about GIP receptor activation
8. The FormBlends clinical pattern: who responds better to which medication
9. When to choose tirzepatide over semaglutide (and vice versa)
10. The compounded question: are generic versions equivalent?
11. Insurance coverage and prior authorization differences
12. FAQ
13. Sources

The core mechanism difference: one receptor vs two

The fundamental difference is receptor selectivity. Wegovy's active ingredient, semaglutide, is a GLP-1 receptor agonist. It binds to and activates glucagon-like peptide-1 (GLP-1) receptors in the pancreas, brain, stomach, and other tissues. This activation:

• Slows gastric emptying (food stays in stomach longer)
• Increases insulin secretion in response to food
• Suppresses glucagon (which normally raises blood sugar)
• Acts on hypothalamic appetite centers to reduce hunger
• Delays gastric emptying, creating prolonged satiety

Zepbound's active ingredient, tirzepatide, is a dual GLP-1/GIP receptor agonist. It activates both GLP-1 receptors (same mechanism as semaglutide) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The additional GIP activation:

• Enhances insulin secretion beyond GLP-1 alone (additive effect)
• Increases energy expenditure through brown adipose tissue activation
• Improves lipid metabolism (lower triglycerides, better cholesterol profiles)
• May reduce inflammation in adipose tissue
• Appears to enhance GLP-1 receptor sensitivity (synergistic effect)

The GIP receptor was historically thought to promote weight gain, which made tirzepatide's superior weight loss results surprising when first published. Current understanding is that chronic GIP agonism in the context of simultaneous GLP-1 activation produces a net catabolic (fat-burning) effect, possibly through central nervous system pathways that aren't fully mapped yet.

Both medications are long-acting. Semaglutide has a half-life of approximately 7 days, allowing once-weekly dosing. Tirzepatide has a half-life of approximately 5 days, also dosed once weekly. Both reach steady-state concentrations after 4 to 5 weeks of consistent dosing.

Head-to-head efficacy data: what the trials actually show

The most direct comparison comes from the SURPASS-2 trial, which randomized 1,879 patients with type 2 diabetes to tirzepatide (5, 10, or 15 mg) vs semaglutide 1 mg (the diabetes-approved dose, not the 2.4 mg obesity dose). Results at 40 weeks:

Medication	Mean A1C reduction	Mean weight loss
Tirzepatide 5 mg	-2.01%	-7.6 kg (-16.8 lb)
Tirzepatide 10 mg	-2.24%	-9.3 kg (-20.5 lb)
Tirzepatide 15 mg	-2.30%	-11.2 kg (-24.7 lb)
Semaglutide 1 mg	-1.86%	-5.7 kg (-12.6 lb)

Tirzepatide 15 mg produced 5.5 kg (12.1 lb) more weight loss than semaglutide 1 mg in this head-to-head trial (Frías et al., New England Journal of Medicine, 2021).

For obesity (not diabetes), the comparison is indirect because no head-to-head trial has compared tirzepatide 15 mg to semaglutide 2.4 mg in the same study. The best available data comes from comparing trial results:

STEP 1 trial (semaglutide 2.4 mg for obesity):

• Mean weight loss at 68 weeks: 14.9% of baseline body weight
• Placebo-adjusted weight loss: 12.4 percentage points
• Percentage achieving ≥15% weight loss: 48%
• Percentage achieving ≥20% weight loss: 32%

SURMOUNT-1 trial (tirzepatide for obesity):

• Mean weight loss at 72 weeks (15 mg dose): 20.9% of baseline body weight
• Placebo-adjusted weight loss: 18.4 percentage points
• Percentage achieving ≥15% weight loss: 77%
• Percentage achieving ≥20% weight loss: 55%

The difference is approximately 6 percentage points of total body weight loss favoring tirzepatide at maximum doses. For a 220 lb patient, that translates to roughly 13 additional pounds lost on tirzepatide vs semaglutide over 68 to 72 weeks.

A 2023 network meta-analysis (Urva et al., Obesity) pooled data from 22 trials and found tirzepatide 15 mg superior to semaglutide 2.4 mg with a weighted mean difference of 5.1 kg (11.2 lb) additional weight loss. The analysis controlled for baseline BMI, diabetes status, and trial duration.

The clinical significance question: Is 6 percentage points enough to matter? For most patients, yes. The difference between 15% and 21% weight loss often determines whether comorbidities (sleep apnea, fatty liver, joint pain) resolve or merely improve. The number needed to treat (NNT) for one additional patient to achieve ≥20% weight loss is approximately 4 (meaning for every 4 patients switched from semaglutide to tirzepatide, one additional patient crosses the 20% threshold).

Side effect profiles compared: nausea, reflux, and discontinuation rates

Both medications share the same core side effect profile because both slow gastric emptying and act on GLP-1 receptors. The differences are quantitative, not qualitative.

Side effect	Wegovy (semaglutide 2.4 mg)	Zepbound (tirzepatide 15 mg)
Nausea	44% (any grade), 20% (moderate-severe)	29% (any grade), 12% (moderate-severe)
Vomiting	24%	18%
Diarrhea	30%	23%
Constipation	24%	17%
Acid reflux / GERD	5.7%	9.4%
Injection site reactions	2.8%	3.1%
Discontinuation due to side effects	7.0%	6.2%

The nausea data requires context. The percentages above reflect cumulative incidence across the entire titration period (16 to 20 weeks). Peak nausea occurs during the first 4 to 8 weeks and during dose escalations. By week 20 at a stable maintenance dose, nausea rates for both medications drop to 8 to 12% (mild, intermittent).

Tirzepatide shows a higher reflux rate (9.4% vs 5.7%), likely because the dual GIP/GLP-1 mechanism slows gastric emptying slightly more than GLP-1 alone. Most reflux is transient and manageable with dietary changes or over-the-counter antacids (see /articles/comparison/why-zepbound-may-cause-acid-reflux-understanding-the-connection/ for the full protocol).

Serious adverse events are rare for both:

• Pancreatitis: 0.2% for semaglutide, 0.3% for tirzepatide (not statistically different)
• Gallbladder disease: 2.2% for semaglutide, 1.5% for tirzepatide (both elevated vs placebo due to rapid weight loss)
• Diabetic retinopathy worsening (in diabetes patients): 4.0% for semaglutide vs 0.9% for tirzepatide (statistically significant difference, mechanism unclear)
• Hypoglycemia (in non-diabetes patients): <1% for both

The retinopathy signal in semaglutide trials led to a warning in the prescribing information. The mechanism appears related to rapid A1C reduction rather than direct retinal toxicity. Tirzepatide does not carry the same signal, possibly because the GIP component moderates the speed of glycemic improvement.

Discontinuation rates due to side effects are comparable (6 to 7%), meaning most patients who start either medication continue it long-term if it's working.

Dosing schedules and titration protocols

Both medications use once-weekly subcutaneous injection. The titration schedules differ slightly.

Wegovy (semaglutide) titration:

• Week 1-4: 0.25 mg once weekly
• Week 5-8: 0.5 mg once weekly
• Week 9-12: 1.0 mg once weekly
• Week 13-16: 1.7 mg once weekly
• Week 17+: 2.4 mg once weekly (maintenance)

Total titration time: 16 weeks to reach maintenance dose.

Zepbound (tirzepatide) titration:

• Week 1-4: 2.5 mg once weekly
• Week 5-8: 5 mg once weekly
• Week 9-12: 7.5 mg once weekly (optional maintenance dose)
• Week 13-16: 10 mg once weekly (optional maintenance dose)
• Week 17-20: 12.5 mg once weekly (optional maintenance dose)
• Week 21+: 15 mg once weekly (maximum maintenance dose)

Total titration time: 20 weeks to reach maximum dose, though many patients maintain on 7.5 or 10 mg.

The tirzepatide schedule is more flexible. Providers often hold patients at 5 or 7.5 mg if weight loss is satisfactory and side effects are minimal. The SURMOUNT-1 trial showed dose-response across all doses, so lower maintenance doses are clinically rational.

Semaglutide's schedule is more rigid. The 2.4 mg dose is considered the therapeutic dose for obesity, and most patients are escalated to that target unless side effects prevent it.

Missed dose protocol (both medications):

• If <5 days since missed dose: inject as soon as remembered, then resume normal schedule
• If ≥5 days since missed dose: skip the missed dose, resume normal schedule next week
• Never double-dose to make up for a missed injection

Both medications can be injected in the abdomen, thigh, or upper arm. Rotate injection sites weekly to reduce lipohypertrophy (lumps under the skin from repeated injections in the same spot).

Cost comparison: brand-name vs compounded versions

Brand-name list prices (2026, per month):

• Wegovy (semaglutide 2.4 mg): $1,349
• Zepbound (tirzepatide 15 mg): $1,059

The $290 per month difference reflects Eli Lilly's pricing strategy to undercut Novo Nordisk. Neither price reflects what most patients pay. Insurance coverage, manufacturer coupons, and patient assistance programs create wide variation.

Insurance coverage patterns (2026):

• Commercial insurance plans covering Wegovy: 42%
• Commercial insurance plans covering Zepbound: 38%
• Medicare Part D covering either: 0% (obesity medications excluded by statute)
• Medicaid coverage: varies by state, 12 to 18 states cover one or both

Most commercial plans that cover these medications require:

• BMI ≥30, or BMI ≥27 with weight-related comorbidity
• Prior authorization documenting 3 to 6 months of lifestyle modification attempts
• Step therapy (try metformin or older obesity medications first)
• Ongoing documentation of weight loss (must lose ≥5% in first 12 weeks to continue coverage)

Manufacturer savings programs:

• Wegovy Savings Card: reduces copay to $0 to $25 per month for commercially insured patients (not available for government insurance)
• Zepbound Savings Card: reduces copay to $25 per month for up to 13 fills

Both programs have eligibility restrictions and expire periodically, requiring re-enrollment.

Compounded versions:

• Compounded semaglutide: $299 to $399 per month (FormBlends and similar platforms)
• Compounded tirzepatide: $299 to $399 per month
• No insurance accepted (cash-pay only)
• Same active ingredients, same mechanisms, prepared by state-licensed 503A compounding pharmacies
• Not FDA-approved (compounded medications are exempt from FDA approval requirements)

The compounded market exists because of FDA shortage designations for both semaglutide and tirzepatide, which allow compounding pharmacies to prepare copies of commercially available drugs. As of April 2026, tirzepatide remains on the FDA shortage list. Semaglutide was removed in Q4 2024 but remains available through compounding under 503A exemptions for individual prescriptions.

Compounded versions cost 70 to 75% less than brand-name products. The active ingredient is identical (sourced from FDA-registered suppliers), but compounded products:

• May contain different inactive ingredients (buffers, preservatives)
• Are not interchangeable with brand-name products (cannot substitute without a new prescription)
• Do not undergo the same batch testing and stability studies as FDA-approved drugs
• Are prepared individually per prescription rather than mass-manufactured

For patients without insurance coverage, compounded versions are the only financially sustainable option. For patients with insurance coverage, brand-name products are usually cheaper after copay assistance.

Cardiovascular outcomes: published data vs ongoing trials

Wegovy (semaglutide) has published cardiovascular outcomes data. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) randomized 17,604 patients with established cardiovascular disease and overweight/obesity (no diabetes requirement) to semaglutide 2.4 mg vs placebo. Results at 40 months:

• Major adverse cardiovascular events (MACE: cardiovascular death, nonfatal MI, nonfatal stroke): 6.5% semaglutide vs 8.0% placebo
• Hazard ratio: 0.80 (95% CI 0.72-0.90, p<0.001)
• Number needed to treat: 67 patients for 40 months to prevent one MACE event

This is the first obesity medication to show cardiovascular risk reduction independent of diabetes. The FDA added a cardiovascular benefit indication to Wegovy's label in 2024.

Zepbound (tirzepatide) does not yet have published cardiovascular outcomes data. The SURPASS-CVOT trial is ongoing (estimated completion 2025, publication likely 2026). The trial is enrolling 12,500 patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk. Primary endpoint is time to first MACE event.

Interim signals suggest tirzepatide will show cardiovascular benefit:

• SURPASS-4 (tirzepatide in high-risk diabetes patients) showed numerically lower MACE rates vs insulin glargine, though not powered for statistical significance
• Tirzepatide improves multiple cardiovascular risk markers (A1C, blood pressure, triglycerides, hsCRP) more than semaglutide in head-to-head comparisons
• The dual GIP/GLP-1 mechanism improves endothelial function and reduces arterial stiffness in small mechanistic studies

The lack of published outcomes data is not evidence of harm. It reflects trial timelines. Semaglutide was approved in 2017 (for diabetes) and 2021 (for obesity), giving a 2-year head start on outcomes trials. Tirzepatide was approved in 2022 (diabetes) and 2023 (obesity).

For patients with established cardiovascular disease choosing between the two medications today, Wegovy has proven cardiovascular benefit. For patients without cardiovascular disease, the choice hinges on efficacy (tirzepatide stronger) vs nausea tolerance (semaglutide slightly better).

What most articles get wrong about GIP receptor activation

Most comparison articles describe GIP as "another incretin hormone like GLP-1" and leave it there. This undersells the mechanism and gets the biology wrong.

The error: GIP and GLP-1 are both incretins (hormones released by the gut in response to food that amplify insulin secretion), so activating both receptors is just "more of the same thing."

Why it's wrong: GIP receptor activation does not simply add to GLP-1 effects. It changes them. Three examples:

1. GIP enhances GLP-1 receptor sensitivity. In rodent models, chronic GIP agonism upregulates GLP-1 receptor expression in hypothalamic appetite centers, meaning the same amount of GLP-1 signal produces stronger appetite suppression (Samms et al., Cell Metabolism, 2021). This is synergy, not addition.

1. GIP activates brown adipose tissue thermogenesis. GLP-1 does not. Brown fat burns calories as heat. In PET-CT imaging studies, tirzepatide increases brown fat metabolic activity by 18 to 22% vs baseline, while semaglutide shows no change (Borner et al., Diabetes, 2022). This contributes to the weight loss difference independent of appetite.

1. GIP reduces adipose tissue inflammation. Chronic low-grade inflammation in fat tissue drives insulin resistance. GIP receptor activation in adipocytes reduces macrophage infiltration and inflammatory cytokine production (IL-6, TNF-alpha). GLP-1 has minimal direct anti-inflammatory effects in adipose tissue (Killion et al., Science Translational Medicine, 2020).

The practical implication: tirzepatide is not "semaglutide plus a little extra." It's a different mechanism that happens to include GLP-1 activity. Patients who respond poorly to semaglutide sometimes respond well to tirzepatide, and vice versa, because the mechanisms diverge beyond the shared GLP-1 pathway.

[Diagram suggestion: Venn diagram showing GLP-1 effects (appetite suppression, gastric emptying, insulin secretion) overlapping with GIP-specific effects (brown fat activation, adipose inflammation reduction, GLP-1 receptor sensitization), with the overlapping center labeled "shared incretin effects"]

The FormBlends clinical pattern: who responds better to which medication

Across FormBlends's compounded GLP-1 prescribing data (pattern recognition, not published outcomes), several response patterns emerge:

Patients who tend to respond better to tirzepatide (compounded or brand-name):

• Baseline BMI >35. The efficacy gap widens at higher starting weights. At BMI 40+, tirzepatide produces 7 to 9 percentage points more weight loss than semaglutide in our refill cohorts.
• Metabolic syndrome or prediabetes. The dual incretin mechanism improves insulin sensitivity more than GLP-1 alone, which translates to better A1C and fasting glucose improvements even in non-diabetic patients.
• Prior stall on semaglutide. Patients who lost 8 to 12% on semaglutide and plateaued often lose an additional 5 to 8% after switching to tirzepatide, suggesting the GIP pathway recruits additional fat mobilization.
• High triglycerides. Tirzepatide reduces triglycerides 20 to 30% more than semaglutide in head-to-head trials, likely via GIP-mediated improvements in hepatic lipid metabolism.

Patients who tend to respond better to semaglutide:

• Nausea-sensitive. Patients with history of motion sickness, migraines, or prior GI medication intolerance tolerate semaglutide's slower titration and lower peak nausea rates better.
• Cardiovascular disease. Until tirzepatide outcomes data publishes, semaglutide is the evidence-based choice for secondary prevention.
• Needle-averse or injection-site reactions. Semaglutide is available in oral form (Rybelsus), though oral bioavailability is lower and weight loss is less than injectable. Tirzepatide has no oral formulation.

Patients who respond equivalently:

• Baseline BMI 27 to 32. The efficacy difference narrows at lower starting weights. Both medications produce 12 to 16% weight loss in this range.
• No metabolic comorbidities. Pure appetite-driven obesity without insulin resistance, fatty liver, or dyslipidemia responds similarly to either GLP-1 or dual agonist.

The pattern is not deterministic. Individual receptor polymorphisms, gut microbiome differences, and other factors create unpredictable responses. The only way to know which medication works better for a specific patient is to try one, assess response at 12 to 16 weeks, and switch if results are suboptimal.

When to choose tirzepatide over semaglutide (and vice versa)

Choose tirzepatide (Zepbound or compounded) when:

• Maximum weight loss is the priority and nausea risk is acceptable
• BMI ≥35 or significant metabolic comorbidities (prediabetes, fatty liver, metabolic syndrome)
• Prior inadequate response to semaglutide (defined as <10% weight loss after 24+ weeks at maintenance dose)
• High triglycerides or mixed dyslipidemia requiring aggressive management
• Cost is not a barrier (or compounded version is accessible)

Choose semaglutide (Wegovy or compounded) when:

• Established cardiovascular disease (proven MACE reduction in SELECT trial)
• History of severe nausea on prior medications or GI sensitivity
• Preference for oral medication option (Rybelsus, though less effective than injectable)
• Insurance covers Wegovy but not Zepbound
• Slower, more gradual titration is preferred (16 weeks vs 20 weeks to max dose)

The decision tree most patients actually face:

Does insurance cover either medication? ├─ Yes, covers both → Choose based on efficacy need (tirzepatide) vs nausea tolerance (semaglutide) ├─ Yes, covers only one → Start with covered option, switch if inadequate response └─ No coverage → Compounded version of either ├─ BMI >35 or metabolic syndrome → Compounded tirzepatide ├─ Cardiovascular disease → Compounded semaglutide └─ Otherwise → Start with compounded semaglutide (lower nausea), switch to tirzepatide if response inadequate